BioVie Announces Phase 2 Study Design for Bezisterim in Long COVID
BioVie Inc. (NASDAQ: BIVI) has made headlines with its recent announcement regarding the design of a planned Phase 2 clinical trial for bezisterim, aimed at treating Long COVID. The company, which specializes in developing advanced therapies for neurological and neurodegenerative diseases, presented this significant development ahead of its presentation at a prominent international conference on Long COVID.
Details of the Planned Phase 2 Study
The upcoming Phase 2 study focuses on evaluating the effectiveness and safety of bezisterim for Long COVID symptoms. This double-blind, randomized, placebo-controlled trial will involve approximately 200 participants, a substantial number aimed at gathering conclusive results. Funded entirely by a grant from the U.S. Department of Defense, the study seeks to assess how a three-month treatment course with bezisterim might alleviate neurocognitive symptoms associated with Long COVID.
Conference Presentation Details
BioVie has confirmed that the abstract detailing their study has been accepted for presentation in poster format. The specifics are:
Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID
Poster Number: 28
Presentation Date: November 21, 2024
Presenter: Penelope Markham, Ph.D., Senior Vice President and Program Lead, Long COVID, BioVie Inc.
Understanding Long COVID
Long COVID is a complex condition that arises after the initial COVID-19 infection. Symptoms can persist long after recovery from the acute phase, affecting nearly 6.8% of adults in the U.S., translating to over 17 million people. This condition is marked by a variety of symptoms such as persistent fatigue, cognitive challenges often referred to as 'brain fog', and loss of smell and taste, among others. Recent evaluate reports indicate that the prevalence might be as high as 22%, emphasizing the need for effective treatments.
The Economic Impact of Long COVID
The repercussions of Long COVID are profound, not just on individual health but also on the economy. The staggering estimated cost of $3.7 trillion highlights the potential role of healthcare providers and pharmaceutical advancements in addressing these long-term challenges. No effective pharmacological or non-pharmacological treatments are currently available, accentuating the urgency for research and development in this arena.
Backing from the U.S. Department of Defense
This Phase 2 study is backed by a substantial award of $13,137,150 via the Peer Reviewed Medical Research Program (PRMRP) granted by the U.S. Department of Defense. Their support showcases the importance of addressing health issues emerging from the COVID pandemic, and highlights BioVie’s commitment to advancing treatment options for such complex conditions.
About BioVie Inc.
BioVie Inc. has been at the forefront of developing cutting-edge therapies for neurological conditions, including Long COVID, Alzheimer’s disease, and Parkinson’s disease. Their innovative approach with bezisterim aims to tackle not just the symptoms but also the underlying neuroinflammation and insulin resistance that contribute to these conditions. Furthermore, BioVie is actively pursuing the clinical evaluation of BIV201, an orphan drug for liver disease treatment, which has garnered FDA Fast Track status.
Frequently Asked Questions
What is the aim of the Phase 2 study for bezisterim?
The Phase 2 study aims to evaluate the safety, tolerability, and potential efficacy of bezisterim in treating neurocognitive symptoms linked to Long COVID.
Who is funding the study?
The study is fully funded by a grant from the U.S. Department of Defense, amounting to $13,137,150.
What are the common symptoms of Long COVID?
Long COVID symptoms can include extreme fatigue, cognitive challenges, loss of taste and smell, and persistent respiratory and cardiovascular issues.
How prevalent is Long COVID among adults in the U.S.?
Recent studies show that approximately 6.8% of adults in the U.S. are currently living with Long COVID, which may potentially be as high as 22% based on real-world data.
What is the significance of BioVie’s research efforts?
BioVie’s research represents a critical step towards developing effective treatments for Long COVID, a condition currently lacking proven pharmacological interventions, highlighting the company's role in addressing post-COVID complications.
